Our Bureau, Chennai Friday, July 4, 2025, 12:45 Hrs [IST] Pharmac South 2025, the 10th edition of South India's high-power ...

Lupin introduces ipratropium bromide nasal solution, 0.03% & 0.06% in US markets: Our Bureau, Mumbai Friday, July 4, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin ...

CytoDyn announces encouraging clinical findings among patients with advanced metastatic colorectal cancer previously treated with leronlimab: Vancouver, Washington Friday, July 4, ...

Nuravax, Institute for Molecular Medicine to present phase 1 results & phase 2 design of Alzheimer’s vaccine AV-1959R at CTAD 2025: Irvine, California Friday, July 4, 2025, 17:0 ...

Jaslok Hospital performs first-of-its-kind lutetium therapy saving terminal prostate cancer patient: Our Bureau, Mumbai Friday, July 4, 2025, 17:15 Hrs [IST] In a first-of-its-kin ...

Jacobio Pharma submits phase I/II IND application for its BET inhibitor, JAB-8263 to treat autoimmune diseases to CDE in China: Beijing, Shanghai Friday, July 4, 2025, 13:00 Hrs [ ...

Lifesciences industry adopts a wait-and-watch approach amid US tariff uncertainty: Aditya Sharma: Nandita Vijayasimha, Friday, July 4, 2025, 08:00 Hrs [IST] Lifesciences industry ...

India and Myanmar in talks to fast-track approval for pharma products in Myanmar: Shardul Nautiyal, Mumbai Friday, July 4, 2025, 08:00 Hrs [IST] In a major development to boost ph ...

NS Pharma announces alliance with Boston Children’s Hospital to develop new therapies for rare diseases: Paramus, New Jersey Friday, July 4, 2025, 12:00 Hrs [IST] Paramus-headqu ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

SonoClear receives US FDA breakthrough designation for its SonoClear system for use in intracranial ultrasound procedures: Oslo, Norway Friday, July 4, 2025, 10:00 Hrs [IST] SonoC ...

Inmagene enrolls first patient in ADAPTIVE phase 2b clinical trial of IMG-007: San Diego Friday, July 4, 2025, 15:00 Hrs [IST] Inmagene Biopharmaceuticals (Inmagene), a clinical-s ...